{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:19:06Z","timestamp":1792095546325,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To report outcomes of photodynamic therapy (PDT) as primary treatment for small amelanotic choroidal melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective interventional case series of 12 patients with small choroidal melanoma treated with standard-fluence PDT (83 seconds; 50 J\/cm<jats:sup>2<\/jats:sup>) using verteporfin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome measures:<\/jats:title>\n            <jats:p>Tumor regression, subretinal fluid resolution, best-corrected visual acuity, and PDT complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were 12 eyes with melanoma, demonstrating amelanotic (10 [83%]) or lightly pigmented (n = 2, 17%) appearance. The mean tumor thickness was 2.7 mm (median, 2.8; range 1.8\u20133.7 mm). After PDT, mean follow-up was 56 months (median, 53; range, 14\u201391). Outcomes revealed complete tumor regression after 1 session (n = 3, 25%), 2 sessions (n = 3, 25%), and 3 sessions (n = 2, 17%) of PDT, reduced to mean thickness of 2.1 mm (median, 2.0; range 1.2\u20133.4 mm). Tumors that failed to regress (n = 4, 33%) were further controlled with transpupillary thermotherapy (n = 1) or plaque brachytherapy (n = 3). Subretinal fluid, present in six eyes, demonstrated resolution (n = 5) or progression (n = 1), and one tumor developed new subretinal fluid after PDT (n = 1). Visual outcome was stable (n = 11 eyes) or improved (n = 1). Photodynamic therapy complications included local retina pigment epithelium atrophy at the site of treatment in 3 (25%) eyes, with no effect on macular or optic nerve function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Primary PDT resulted in complete tumor regression of small amelanotic choroidal melanoma in 67% at mean 5 years, with no major effect on visual acuity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002169","type":"journal-article","created":{"date-parts":[[2018,4,15]],"date-time":"2018-04-15T21:28:30Z","timestamp":1523827710000},"page":"1319-1325","source":"Crossref","is-referenced-by-count":39,"title":["PHOTODYNAMIC THERAPY AS PRIMARY TREATMENT FOR SMALL CHOROIDAL MELANOMA"],"prefix":"10.1097","volume":"39","author":[{"given":"Elif B.","family":"Turkoglu","sequence":"first","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"},{"name":"Akdeniz University School of Medicine, Antalya, Turkey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renelle","family":"Pointdujour-Lim","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"},{"name":"Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Mashayekhi","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.survophthal.2015.05.004","article-title":"Clinical use of photodynamic therapy in ocular tumors","volume":"60","author":"Cerman","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/IAE.0000000000001202","article-title":"Photodynamic therapy for choroidal nevus with subfoveal fluid","volume":"37","author":"Pointdujour-Lim","year":"2017","journal-title":"Retina"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/IAE.10.1097\/IAE.0b013e31822c28ec","article-title":"Treatment of amelanotic choroidal melanoma with photodynamic therapy","volume":"32","author":"Campbell","year":"2012","journal-title":"Retina"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/IAE.0b013e31825097c1","article-title":"Clinical and histopathologic findings after photodynamic therapy of choroidal melanoma","volume":"32","author":"Canal-Fontcuberta","year":"2012","journal-title":"Retina"},{"key":"R5-20230816","first-page":"871","article-title":"Photodynamic therapy of pigmented choroidal melanomas","volume":"36","author":"Gonzalez","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3928\/15428877-20120426-01","article-title":"Dramatic regression of amelanotic choroidal melanoma with PDT following poor response to brachytherapy","volume":"43","author":"Tuncer","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"339","DOI":"10.18388\/abp.2005_3447","article-title":"Direct tumor damage mechanisms of photodynamic therapy","volume":"52","author":"Nowis","year":"2005","journal-title":"Acta Biochim Pol"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000101922","article-title":"Ocular photodynamic therapy standard applications and new indications (part 1). Review of the literature and personal experience","volume":"221","author":"Mennel","year":"2007","journal-title":"Ophthalmologica"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/archopht.1984.01040030653011","article-title":"Hematoporphyrin photoradiation therapy for intraocular and orbital malignant melanoma","volume":"102","author":"Tse","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R10-20230816","first-page":"491","article-title":"Photodynamic therapy of pigmented choroidal melanomas in rabbits","volume":"38","author":"Hu","year":"2002","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0161-6420(13)31242-1","article-title":"Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin","volume":"101","author":"Schmidt-Erfurth","year":"1994","journal-title":"Ophthalmology"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10637-012-9844-4","article-title":"The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57\/BL6 mice","volume":"31","author":"Rapozzi","year":"2013","journal-title":"Invest New Drugs"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0002-9394(02)02222-5","article-title":"Treatment of choroidal melanoma using photodynamic therapy","volume":"135","author":"Barbazetto","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00347-004-1092-3","article-title":"Photodynamic therapy with verteporfin for uveal melanoma","volume":"102","author":"Wachtlin","year":"2005","journal-title":"Ophthalmologe"},{"key":"R15-20230816","first-page":"145","article-title":"Photodynamic therapy with verteporfin in subfoveal amelanotic choroidal melanoma (a controlled case)","volume":"27","author":"Soucek","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/bjophthalmol-2013-304432","article-title":"Treatment of posterior uveal melanoma with multi-dose photodynamic therapy","volume":"98","author":"Rundle","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1097\/IAE.0000000000001048","article-title":"Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: functional Outcomes and Local Tumor Control","volume":"36","author":"Blasi","year":"2016","journal-title":"Retina"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report No 19","volume":"109","author":"Jampol","year":"2002","journal-title":"Ophthalmology"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamaophthalmol.2014.111","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases","volume":"132","author":"Sagoo","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ophtha.2014.09.029","article-title":"Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control","volume":"122","author":"Mashayekhi","year":"2015","journal-title":"Ophthalmology"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0161-6420(01)00902-2","article-title":"Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations","volume":"109","author":"Shields","year":"2002","journal-title":"Ophthalmology"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1442-9071.2005.01083.x","article-title":"Primary treatment of choroidal amelanotic melanoma with photodynamic therapy","volume":"33","author":"Donaldson","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0002-9394(77)90133-7","article-title":"Proton irradiation of small choroidal malignant melanomas","volume":"83","author":"Gragoudas","year":"1977","journal-title":"Am J Ophthalmol"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0360-3016(01)01560-7","article-title":"Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma","volume":"51","author":"Egger","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clon.2016.01.034","article-title":"Clinical outcomes of proton radiotherapy for uveal melanoma","volume":"28","author":"Verma","year":"2016","journal-title":"Clin Oncol"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/eye.2017.22","article-title":"Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma","volume":"31","author":"Fabian","year":"2017","journal-title":"Eye"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008390-199510000-00009","article-title":"Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture","volume":"5","author":"Favilla","year":"1995","journal-title":"Melanoma Res"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/archopht.118.3.360","article-title":"Combination of clinical factors predictive of growth of small choroidal melanocytic tumors","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.1997.01100160707007","article-title":"Factors predictive of growth and treatment of small choroidal melanoma: COMS report No. 5","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R31-20230816","first-page":"43","article-title":"Long-term risk of local failure after proton therapy for choroidal\/ciliary body melanoma","volume":"100","author":"Gragoudas","year":"2002","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201907000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:18:00Z","timestamp":1692231480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201907000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002169","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}